- Home
- JELD vs PRQR Comparison
JELD vs PRQR Comparison
Compare JELD & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | PRQR |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 244.1M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JELD | PRQR |
|---|---|---|
| Price | $1.08 | $1.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.43 | ★ $7.25 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.33 |
| 52 Week High | $6.98 | $3.10 |
Technical Indicators
Market Signals| Indicator | JELD | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 50.08 |
| Support Level | $0.93 | $1.37 |
| Resistance Level | $2.06 | $1.76 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 6.25 | 43.30 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.